The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy

Epstein-Barr virus (EBV)-immortalised B cell lines were established from patients receiving multiple administrations (two or more) of radiolabelled murine monoclonal antibodies for the treatment of ovarian cancer. Cells secreting anti-id super(2) Ig, an immunoglobulin with binding specificities comp...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1990-01, Vol.62, p.85-88
Main Authors: Kosmas, C, Man, S, Epenetos, A A, Courtenay-Luck, N S
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epstein-Barr virus (EBV)-immortalised B cell lines were established from patients receiving multiple administrations (two or more) of radiolabelled murine monoclonal antibodies for the treatment of ovarian cancer. Cells secreting anti-id super(2) Ig, an immunoglobulin with binding specificities comparable to the administered murine monoclonal antibody, were isolated by using magnetic beads coated with tumour-associated antigen, incubated with the cells and concentrated with a magnetic particle concentrator. Cross-linking of the immunoglobulin receptors by the antigen-coated beads appears to stimulate proliferation, resulting in increased secretion of the human anti-tumour-associated antigen antibodies. The T cell responses were studied and it was found that monoclonal antibody therapy appears to lead to an increase in the population of T cells committed to proliferate in response to both specific antigen and non-specific mitogens.
ISSN:0007-0920